Header Image

Investor Relations

Investor Relations

Investor Relations

Corporate Profile

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, email us.

NASDAQ: BCRX
$4.52 - 0.11
Nov 17, 2017 at 4:00 PM ET
Intraday data provided by eSignal

News

Nov 16, 2017
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to pro...
Read More
Nov 7, 2017
BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- B...
Read More

Investor Relations

Thomas Staab, Senior Vice President,
Chief Financial Officer
919.859.7910
investorrelations@biocryst.com

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)